Novogen (NASDAQ:KZIA) Announces Quarterly Earnings Results

Novogen (NASDAQ:KZIA – Get Free Report) announced its quarterly earnings data on Tuesday. The company reported ($0.51) EPS for the quarter, FiscalAI reports.

Novogen Trading Up 3.4%

KZIA stock opened at $5.49 on Thursday. The company has a fifty day simple moving average of $8.59 and a two-hundred day simple moving average of $10.49. Novogen has a 52 week low of $4.86 and a 52 week high of $17.40.

Wall Street Analyst Weigh In

KZIA has been the subject of a number of analyst reports. Canaccord Genuity Group started coverage on shares of Novogen in a report on Thursday, August 13th. They set a “buy” rating and a $29.00 price objective for the company. Guggenheim initiated coverage on Novogen in a report on Wednesday, October 21st. They issued a “buy” rating and a $35.00 target price for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Novogen in a report on Thursday, October 15th. BTIG Research restated a “buy” rating and set a $40.00 price target on shares of Novogen in a research report on Thursday, September 10th. Finally, Needham & Company LLC began coverage on shares of Novogen in a report on Friday, October 30th. They issued a “buy” rating and a $27.00 price target on the stock. Eight analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Novogen presently has a consensus rating of “Moderate Buy” and a consensus price target of $29.50.

Check Out Our Latest Stock Report on Novogen

About Novogen

(Get Free Report)

Novogen Limited, now known as Kazia Therapeutics, is an Australian biotechnology company focused on developing therapies for cancer. The company has historically advanced drug candidates aimed at treating tumors with limited treatment options, rather than marketing approved medicines. Its pipeline has included paxalisib, an investigational drug designed to inhibit the PI3K and mTOR pathways and studied for brain cancers, including glioblastoma. Kazia has also developed other experimental oncology candidates, including cantrixil for ovarian cancer.

Read More

Receive News & Ratings for Novogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novogen and related companies with MarketBeat.com's FREE daily email newsletter.